$ cat ./records/founded-target-malaria-the-worlds-first-gene-drive-research-conso-2005.txt
Founded Target Malaria — the world's first gene drive research consortium targeting malaria mosquitoes
[RECORD.TXT] · cat --full
With foundational Gates Foundation funding, Target Malaria was established as an international research consortium headquartered at Imperial College London. Its mission: develop and deploy gene drive technology to reduce or eliminate populations of Anopheles gambiae — the primary malaria-transmitting mosquito — across sub-Saharan Africa. Over its lifetime, Target Malaria received the majority of its $173 million budget from the Gates Foundation. It represented the most ambitious genetic intervention in vector control history, blending molecular biology, field ecology, regulatory science, and community engagement across multiple African countries.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Called for complete removal of H-1B visa caps, stating 'I don't think there should be any limit'
Next →
Gates Foundation-Backed Consortium Publishes Complete Genome of Theileria parva — Opening Path to Designed ECF Vaccines
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.